Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (1349.HK)
HKD 2.57
(5.76%)
HKD 2.57
(5.76%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 97.08 Million CNY | -27.15% |
| 2022 | 133.27 Million CNY | -38.69% |
| 2021 | 217.37 Million CNY | 25.63% |
| 2020 | 173.03 Million CNY | -30.08% |
| 2019 | 247.48 Million CNY | 64.7% |
| 2018 | 150.26 Million CNY | 97.71% |
| 2017 | 76 Million CNY | -51.0% |
| 2016 | 155.11 Million CNY | 1.35% |
| 2015 | 153.05 Million CNY | 17.77% |
| 2014 | 129.96 Million CNY | 19.93% |
| 2013 | 108.36 Million CNY | 69.67% |
| 2012 | 63.86 Million CNY | 50.31% |
| 2011 | 42.48 Million CNY | 512.94% |
| 2010 | 6.93 Million CNY | 237.27% |
| 2009 | -5.05 Million CNY | 76.67% |
| 2008 | -21.64 Million CNY | 19.08% |
| 2007 | -26.75 Million CNY | -25.54% |
| 2006 | -21.3 Million CNY | 32.9% |
| 2005 | -31.75 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 71.03 Million CNY | 5869.03% |
| 2024 Q1 | 1.19 Million CNY | -90.83% |
| 2023 Q1 | 3.48 Million CNY | -96.6% |
| 2023 Q2 | 59.8 Million CNY | 1617.63% |
| 2023 FY | 97.08 Million CNY | -27.15% |
| 2023 Q3 | 20.83 Million CNY | -65.16% |
| 2023 Q4 | 12.97 Million CNY | -37.72% |
| 2022 Q2 | -64.69 Million CNY | -1362.75% |
| 2022 Q4 | 102.51 Million CNY | 12.0% |
| 2022 FY | 133.27 Million CNY | -38.69% |
| 2022 Q3 | 91.52 Million CNY | 241.48% |
| 2022 Q1 | -4.42 Million CNY | -107.15% |
| 2021 FY | 217.37 Million CNY | 25.63% |
| 2021 Q1 | -3.36 Million CNY | -104.98% |
| 2021 Q2 | 54.19 Million CNY | 1709.39% |
| 2021 Q3 | 50.03 Million CNY | -7.67% |
| 2021 Q4 | 61.85 Million CNY | 23.62% |
| 2020 FY | 173.03 Million CNY | -30.08% |
| 2020 Q3 | 71 Million CNY | 140.44% |
| 2020 Q2 | 29.53 Million CNY | 251.43% |
| 2020 Q1 | -19.5 Million CNY | -114.26% |
| 2020 Q4 | 67.56 Million CNY | -4.85% |
| 2019 Q2 | 95.98 Million CNY | 5030.21% |
| 2019 Q1 | 1.87 Million CNY | -91.27% |
| 2019 Q4 | 136.77 Million CNY | 305.26% |
| 2019 FY | 247.48 Million CNY | 64.7% |
| 2019 Q3 | 33.74 Million CNY | -64.84% |
| 2018 Q4 | 21.43 Million CNY | 0.0% |
| 2018 FY | 150.26 Million CNY | 97.71% |
| 2018 Q2 | 24.51 Million CNY | 0.0% |
| 2018 Q3 | 21.43 Million CNY | -12.59% |
| 2018 Q1 | 24.51 Million CNY | 226.48% |
| 2017 Q3 | 7.51 Million CNY | -68.8% |
| 2017 Q4 | 7.51 Million CNY | 0.0% |
| 2017 Q2 | 24.07 Million CNY | 0.0% |
| 2017 Q1 | 24.07 Million CNY | -51.6% |
| 2017 FY | 76 Million CNY | -51.0% |
| 2016 Q3 | 49.73 Million CNY | 119.53% |
| 2016 Q2 | 22.65 Million CNY | 0.0% |
| 2016 Q1 | 22.65 Million CNY | -56.07% |
| 2016 FY | 155.11 Million CNY | 1.35% |
| 2016 Q4 | 49.73 Million CNY | 0.0% |
| 2015 FY | 153.05 Million CNY | 17.77% |
| 2015 Q4 | 51.56 Million CNY | 0.0% |
| 2015 Q2 | 18.94 Million CNY | 0.0% |
| 2015 Q3 | 51.56 Million CNY | 172.24% |
| 2015 Q1 | 18.94 Million CNY | -15.79% |
| 2014 Q3 | 22.49 Million CNY | 20.44% |
| 2014 Q4 | 22.49 Million CNY | 0.0% |
| 2014 FY | 129.96 Million CNY | 19.93% |
| 2014 Q1 | 18.67 Million CNY | -57.43% |
| 2014 Q2 | 18.67 Million CNY | 0.0% |
| 2013 Q2 | 24.33 Million CNY | 150.6% |
| 2013 Q4 | 43.87 Million CNY | 44.18% |
| 2013 FY | 108.36 Million CNY | 69.67% |
| 2013 Q1 | 9.71 Million CNY | -65.53% |
| 2013 Q3 | 30.43 Million CNY | 25.04% |
| 2012 FY | 63.86 Million CNY | 50.31% |
| 2012 Q4 | 28.17 Million CNY | 63.5% |
| 2012 Q3 | 17.23 Million CNY | 28.06% |
| 2012 Q2 | 13.45 Million CNY | 168.72% |
| 2012 Q1 | 5 Million CNY | -86.29% |
| 2011 Q3 | 5.32 Million CNY | 146.0% |
| 2011 FY | 42.48 Million CNY | 512.94% |
| 2011 Q1 | -1.52 Million CNY | -119.13% |
| 2011 Q2 | 2.16 Million CNY | 242.12% |
| 2011 Q4 | 36.52 Million CNY | 586.47% |
| 2010 FY | 6.93 Million CNY | 237.27% |
| 2010 Q4 | 7.95 Million CNY | 437.7% |
| 2010 Q3 | 1.48 Million CNY | 68.56% |
| 2010 Q2 | 878 Thousand CNY | 125.95% |
| 2010 Q1 | -3.38 Million CNY | 0.0% |
| 2009 Q2 | -2.13 Million CNY | 0.0% |
| 2009 FY | -5.05 Million CNY | 76.67% |
| 2008 FY | -21.64 Million CNY | 19.08% |
| 2007 FY | -26.75 Million CNY | -25.54% |
| 2006 FY | -21.3 Million CNY | 32.9% |
| 2005 FY | -31.75 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 143.01 Million HKD | 32.111% |
| Grand Pharmaceutical Group Limited | 2.66 Billion HKD | 96.355% |
| Extrawell Pharmaceutical Holdings Limited | -8.16 Million HKD | 1289.533% |
| Wai Yuen Tong Medicine Holdings Limited | 40.88 Million HKD | -137.499% |
| Qianhai Health Holdings Limited | -52.18 Million HKD | 286.056% |
| Lee's Pharmaceutical Holdings Limited | 36.04 Million HKD | -169.379% |
| Essex Bio-Technology Limited | 310.32 Million HKD | 68.714% |
| Tongfang Kontafarma Holdings Limited | - HKD | -Infinity% |
| PuraPharm Corporation Limited | -66.04 Million HKD | 247.003% |
| SSY Group Limited | 1.63 Billion HKD | 94.076% |
| JBM (Healthcare) Limited | 174.2 Million HKD | 44.267% |
| Jacobson Pharma Corporation Limited | 333.12 Million HKD | 70.855% |
| China Resources Pharmaceutical Group Limited | 12.14 Billion HKD | 99.201% |